Scienture (NASDAQ:SCNX) & Summit Therapeutics (NASDAQ:SMMT) Head-To-Head Survey

Scienture (NASDAQ:SCNX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Institutional and Insider Ownership

5.7% of Scienture shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 21.4% of Scienture shares are owned by insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Scienture and Summit Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$140,000.00	146.01	$9.07 million	($1.00)	-0.50
Summit Therapeutics	N/A	N/A	-$221.32 million	($1.24)	-14.63

Scienture has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Scienture and Summit Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	0	0	1.00
Summit Therapeutics	3	4	10	1	2.50

Summit Therapeutics has a consensus target price of $31.77, suggesting a potential upside of 75.13%. Given Summit Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Scienture.

Volatility & Risk

Scienture has a beta of 2.95, suggesting that its share price is 195% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.53, suggesting that its share price is 253% less volatile than the S&P 500.

Profitability

This table compares Scienture and Summit Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	-10,364.22%	-25.18%	-19.22%
Summit Therapeutics	N/A	-311.15%	-262.35%

Summary

Scienture beats Summit Therapeutics on 8 of the 14 factors compared between the two stocks.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.